X0708 D LIVE 0001721484 Longeveron Inc. 1951 NW 7TH AVENUE SUITE 520 MIAMI FL FLORIDA 33136 305-909-0840 DELAWARE LONGEVERON LLC Corporation true Stephen H. Willard 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Executive Officer Joshua M. Hare 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Executive Officer Director Lisa A. Locklear 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Executive Officer Nataliya Agafonova 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Executive Officer Paul Lehr 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Executive Officer Devin Blass 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Executive Officer Rock Soffer 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Director Ursula Ungaro 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Director Roger Joseph Hajjar 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Director George Paletta, Jr. 1951 NW 7th Avenue Suite 520 Miami FL FLORIDA 33136 Director Biotechnology Decline to Disclose 06b false 2026-03-11 false true true true true An interest in 50% of proceeds received (after deducting fees) from the potential future sale of a Rare Pediatric Disease Priority Review Voucher, to the extent received from the U.S. FDA in connection with the Company's laromestrocel program for HLHS. false 0 H.C. Wainwright & Co., LLC 375 Charles Worthman 516096 430 Park Avenue 4th Floor New York NY NEW YORK 10022 CA CALIFORNIA CO COLORADO NY NEW YORK TX TEXAS false H.C. Wainwright & Co., LLC 375 Noam Rubinstein 4070245 430 Park Avenue 4th Floor New York NY NEW YORK 10022 CA CALIFORNIA CO COLORADO NY NEW YORK TX TEXAS false H.C. Wainwright & Co., LLC 375 Craig Schwabe 3137679 430 Park Avenue 4th Floor New York NY NEW YORK 10022 CA CALIFORNIA CO COLORADO NY NEW YORK TX TEXAS false H.C. Wainwright & Co., LLC 375 Michael Vasinkevich 2843810 430 Park Avenue 4th Floor New York NY NEW YORK 10022 CA CALIFORNIA CO COLORADO NY NEW YORK TX TEXAS false 33515000 15890000 17625000 Total offering amount: purchase price of shares of Class A common stock, Series A Preferred Stock, an interest in future proceeds from a potential future PRV sale, proceeds due to Company assuming cash exercise of all warrants issued to placement agent false 7 2224600 true 0 At initial closing, placement agent received $1,112,300.01 & warrants to purchase up to 2,019,231 shares of Common Stock exercisable at $0.65 per share, among other items. Contingent upon a second closing, placement agent will receive an identical comp. 0 false Longeveron Inc. /s/ Lisa A. Locklear Lisa A. Locklear Chief Financial Officer 2026-03-25